View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 24, 2022

BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial

In the trial, the safety, tolerability, and initial efficacy of BV-101 in adult patients with early-stage HD will be evaluated.

Asklepios BioPharmaceutical (AskBio) subsidiary BrainVectis has obtained clearance from the French National Agency for Safety of Medicines and Health Products (ANSM) to carry out the Phase I/II clinical trial of its new gene therapy, BV-101, for treating Huntington’s disease (HD). 

The authorisation, along with the French Ethics Committee in charge’s approval for the trial protocol, will aid in commencing subject recruitment in the trial.

The dose-escalation, open-label trial will evaluate the safety, tolerability, and initial efficacy of BV-101 in adult patients with early-stage HD.

Set to commence in Paris in the fourth quarter of this year, the trial anticipates enrolling 12 to 18 subjects.

A new adeno-associated virus (AAV) gene therapy vector, BV-101 addresses diseased neurons’ metabolic dysfunction and aids in clearing mutant huntingtin proteins at the same time. 

It is given through magnetic resonance imaging (MRI)-guided neurosurgical approaches to act on tissues in the brain’s basal structures. 

The gene therapy showed the potential for repairing the vital cholesterol pathway, providing neuroprotection, and restoring physical performance by delivering CYP46A1, in preclinical research in mice.

An enzyme in the brain, CYP46A1 is found to be low in HD patients. 

BrainVectis founder Nathalie Cartier-Lacave said: “Unlike other attempts to treat Huntington’s Disease, BV-101 aims to restore cholesterol metabolism, reduce mutant huntingtin, and to improve neuronal function. 

“Importantly, BV-101 does not affect the levels of normal huntingtin protein in cells. 

“If this proves successful, we have the potential to change the course of a devastating disease that causes severe functional and cognitive decline.”

There are currently no approved disease-modifying therapies for HD that exist.

Anomalous repeating mutations in the huntingtin gene cause abnormal protein build-up in nerve cells, resulting in this rare, inherited, neurodegenerative ailment.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena